UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model

OBJECTIVES: In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Palace, Jacqueline, Bregenzer, Thomas, Tremlett, Helen, Oger, Joel, Zhu, Fheng, Boggild, Mike, Duddy, Martin, Dobson, Charles
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2014
Assuntos:
Neurology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3902459/
https://ncbi.nlm.nih.gov/pubmed/24441054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2013-004073
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares